Technology News and Research

RSS

KINAXO, AstraZeneca enter oncology research collaboration

KINAXO Biotechnologies GmbH announced today that it has entered into a collaboration with AstraZeneca. Under the terms of the agreement, KINAXO will apply its technology platform to support one of AstraZeneca's oncology programs. KINAXO will employ high-end mass spectrometry-based technologies to quantitatively analyze posttranslational protein modifications on a proteome-wide scale.

5 Jan 2011

OrbusNeich expands patent protection for Genous endothelial progenitor cell capture technology

OrbusNeich today announced that the United States Patent and Trademark Office (USPTO) has granted an additional patent expanding protection of the company's Genous endothelial progenitor cell (EPC) capture technology.

5 Jan 2011

Alkeus and Columbia University enter license agreement for potential therapies for dry-AMD, Stargardt disease

Alkeus Pharmaceuticals and Columbia University announced today that they have entered into a license agreement for a set of potential therapies for the treatment of dry age-related macular degeneration (dry-AMD), Stargardt disease, and other degenerative diseases of the eye. Left untreated, these conditions often lead to impaired vision and even blindness.

5 Jan 2011

ReproCELL to enter collaborative iPS cell-derived hepatocytes R&D agreement with NIBIO

ReproCELL, Inc. (CEO: Chikafumi Yokoyama PhD) announces today that the company will enter a collaborative R&D agreement with the National Institute of Biomedical Innovation (NIBIO; Director General: Koichi Yamanishi; Osaka, Japan), which could offer new hepatocyte derived from human iPS (induced pluripotent stem) cells used for an effective in-vitro drug screening for hepatic toxicity and liver metabolism.

5 Jan 2011

DBV Technologies secures $25.5 million in Series C financing round

DBV Technologies, an emerging biotechnology company, announced today that it has secured $25.5 million (€19,4 million) in a Series C financing round. The round was co-led by new investors InnoBio Fund (managed by CDC Entreprises within FSI France Investment program) and Lundbeckfond Ventures.

5 Jan 2011

Qualcomm's wireless Internet of Everything Module integrated into Telcare 3GM blood glucose meter

Qualcomm Incorporated and Telcare Incorporated today announced plans to integrate Qualcomm's wireless Internet of Everything Module (IEM) into the Telcare 3GM™ blood glucose meter being developed by Telcare. Telcare 3GM, currently in prototype phase, is designed to transfer blood glucose readings to a patient's family members or physician with each test.

5 Jan 2011

Santaris Pharma, Pfizer expand RNA-targeted medicine collaboration

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, and Pfizer Inc., today announced that the companies have expanded their collaboration directed to the development and commercialization of RNA-targeted medicines using Santaris Pharma A/S Locked Nucleic Acid (LNA) Drug Platform.

5 Jan 2011

New wound care eLearning Portal for clinicians

Derma Sciences, a medical device and pharmaceutical company focused on advanced wound care, announces the launch of a new eLearning Portal to provide clinicians with valuable educational programs to ensure they are kept abreast of the latest information and product solutions in the Company's advanced wound care line.

5 Jan 2011

FDA approves Gore's C3 Delivery System to deploy EXCLUDER AAA Endoprosthesis

W. L. Gore & Associates (Gore) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market the GORE® C3 Delivery System to deploy the GORE® EXCLUDER® AAA Endoprosthesis as a minimally invasive treatment for patients suffering from an abdominal aortic aneurysm (AAA).

5 Jan 2011

VENENUM Biodesign relocates to new, state-of-the-art facility in Hamilton

VENENUM Biodesign, a drug discovery company that utilizes ultra-high throughput screening (UHTS) of its compound collection to identify hits against its novel disease-based targets or its partners' targets, announced today its relocation to a brand-new, state-of-the-art facility in Hamilton, NJ in Mercer County.

5 Jan 2011

Towers Watson acquires Aliquant

Towers Watson, a leading global professional services company, announced today the completion of its acquisition of Aliquant, a privately held, full-service health and welfare benefits administration outsourcing firm. The acquisition enables Towers Watson to strengthen its position as a premier provider of high-quality health and welfare benefits outsourcing services.

5 Jan 2011

Tiny light source and sensors in endoscope may detect esophageal cancer more accurately

A tiny light source and sensors at the end of an endoscope may provide a more accurate way to identify pre-cancerous cells in the lining of the esophagus.

4 Jan 2011

Bioniche Life Sciences announces completion of Australian Offer and raises gross proceeds of A$12.5 million

Bioniche Life Sciences In., a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has successfully completed its Australian Offer of 8.6 million CHESS Depositary Instruments at A$1.45 per CDI, raising gross proceeds of A$12.5 million.

4 Jan 2011

Single cancer cell could be detected in future using new test

Soon scientists will be able to detect a single cancer cell among the billions of cells that circulate in the human bloodstream. The method could detect whether the therapy has worked or even show which therapy would work best. The test depends on circulating tumor cells (CTCs) or cancer cells that have detached from the main tumor and are traveling to other parts of the body.

4 Jan 2011

Star Scientific develops moist snuff tobacco product with low carcinogenic levels

Star Scientific, Inc. reports that it has successfully developed a moist snuff tobacco product that has extremely low levels of carcinogens -- much lower than any snuff products currently in the marketplace. This new product has levels of tobacco-specific nitrosamines (TSNAs) -- recognized by scientists worldwide as one of the most powerful cancer-causing agents in tobacco leaf and smoke -- below 20 parts per billion (nanograms-per-gram moist weight, as used) in initial testing.

4 Jan 2011

Revolutions Medical reworks exclusive license with Traxyz for breast biopsy localization system

Revolutions Medical Corporation recently completed the reworking of a worldwide exclusive license with Traxyz, LLC for an image guided navigation system to convert over 50,000 conventional mammography systems for use as a high accuracy breast biopsies system (BBS). This BBS facilitates accurate and fast non-palpable lesions and micro calcification localization in the treatment of breast cancer.

4 Jan 2011

Isis commences ISIS-EIF4ERx Phase 2 studies in non-small cell lung cancer and prostate cancer

Isis Pharmaceuticals, Inc. announced the initiation of two Phase 2 studies of ISIS-EIF4ERx in patients with non-small cell lung cancer and prostate cancer. These studies are part of Isis' broad Phase 2 development program designed to evaluate ISIS-EIF4ERx in multiple types of cancer. ISIS-EIF4ERx targets eukaryotic initiation factor-4E (eIF-4E), a traditionally "undruggable" target that is thought to promote tumor growth and metastasis in many cancers.

4 Jan 2011

STAAR Surgical exceeds 200,000 Visian ICL global implants

STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced that the worldwide total number of Visian® ICL implants in patients has exceeded 200,000. Since 1994, STAAR's Implantable Collamer® Lenses (ICLs) have been used in refractive eye surgery as an alternative to LASIK. Manufactured with STAAR's proprietary Collamer material, Visian ICLs provide a safe and effective alternative in the permanent correction of myopia, hyperopia, and in the case of the Toric ICL, astigmatism.

4 Jan 2011

Caution over frequent use of diagnostic tests for kids

The rapid growth in use of medical diagnostic imaging, such as CT scans, has led to widespread concern about radiation exposure in adults and the potential for future cancer risk in patients undergoing these tests.

4 Jan 2011

New options in fertility preservation for oncology patients

Many young people who've just learned that they have cancer also are told that the therapies that may save their lives could rob them of their ability ever to have children. Infertility caused by chemotherapy and radiation affects a sizable population: Of the 1.5 million people diagnosed with cancer in 2009, nearly 10 percent were still in their reproductive years.

4 Jan 2011

Technology News and Research

KINAXO, AstraZeneca enter oncology research collaboration

OrbusNeich expands patent protection for Genous endothelial progenitor cell capture technology

Alkeus and Columbia University enter license agreement for potential therapies for dry-AMD, Stargardt disease

ReproCELL to enter collaborative iPS cell-derived hepatocytes R&D agreement with NIBIO

DBV Technologies secures $25.5 million in Series C financing round

Qualcomm's wireless Internet of Everything Module integrated into Telcare 3GM blood glucose meter

Santaris Pharma, Pfizer expand RNA-targeted medicine collaboration

New wound care eLearning Portal for clinicians

FDA approves Gore's C3 Delivery System to deploy EXCLUDER AAA Endoprosthesis

VENENUM Biodesign relocates to new, state-of-the-art facility in Hamilton

Towers Watson acquires Aliquant

Tiny light source and sensors in endoscope may detect esophageal cancer more accurately

Bioniche Life Sciences announces completion of Australian Offer and raises gross proceeds of A$12.5 million

Single cancer cell could be detected in future using new test

Star Scientific develops moist snuff tobacco product with low carcinogenic levels

Revolutions Medical reworks exclusive license with Traxyz for breast biopsy localization system

Isis commences ISIS-EIF4ERx Phase 2 studies in non-small cell lung cancer and prostate cancer

STAAR Surgical exceeds 200,000 Visian ICL global implants

Caution over frequent use of diagnostic tests for kids

New options in fertility preservation for oncology patients

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News